Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Melanoma 50Carcinoma, Non-Small-Cell Lung 50Carcinoma, Renal Cell 37Carcinoma, Hepatocellular 20Neoplasm Metastasis 19Lung Neoplasms 19Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Stomach Neoplasms 15Colorectal Neoplasms 15Carcinoma, Transitional Cell 14Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 10Hodgkin Disease 10Brain Neoplasms 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Multiple Myeloma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Colonic Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Basal Cell 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Thyroid Neoplasms 5Sarcoma 5

Interventions

Nivolumab 3tivozanib 1regorafenib 1neratinib 1lutetium Lu 177 dotatate 1encorafenib 1durvalumab 1capivasertib 1Valproic Acid 1Thioctic Acid 1Oxaliplatin 1Multiparametric Magnetic Resonance Imaging 1Leucovorin 1Lenalidomide 1Gemcitabine 1Fulvestrant 1Folfox protocol 1Fluorouracil 1Cisplatin 1Cetuximab 1Bortezomib 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Disease Progression × Nivolumab × 90 days × Clear all
NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
38 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

NCT03259867 2026-04-16

TATE-PD1

Teclison Ltd.

Phase 2 Recruiting
54 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡